MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep into the nasal cavity for the treatment of certain types of chronic sinusitis. XHANCE is also being evaluated in phase III clinical studies as a treatment for all forms of chronic sinusitis. If successful, XHANCE would be the first drug therapy approved by the FDA for the treatment of all forms of chronic sinusitis, a condition that affects over eight million US patients.
Most chronic sinusitis patients are initially prescribed over-the-counter intranasal steroid sprays which are typically inadequate because they don’t reach the sinuses, which are located deep in the nasal cavity. Patients are then left with poor treatment options, including: systemic steroids, invasive surgery, or very expensive biologic drugs.
XHANCE provides patients with a new, effective alternative which avoids the complications and limitations of these other treatments. Adoption of XHANCE has been robust with annual revenue approaching $70 million and demonstrated strong revenue growth throughout 2021.
Optinose is based in Yardely, Pennsylvania. The company plans to appoint Drs. Eric Bednarski and Kyle Dempsey to the board.
VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023
SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]
CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition
July 14, 2023
BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]
Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023
ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]
eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023
New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]
GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023
TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]
OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023
OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]
VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023
Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]
VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023
VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]
MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022
BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]